These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 35891160)

  • 1. The Concordance between Mumps and Rubella Sero-Positivity among the Israeli Population in 2015.
    Bassal R; Shohat T; Levin T; Pando R; Shinar E; Amichay D; Barak M; Ben-Dor A; Bar-Haim A; Mendelson E; Cohen D; Keinan-Boker L; Indenbaum V
    Vaccines (Basel); 2022 Jun; 10(7):. PubMed ID: 35891160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Seroprevalence of antibodies against measles, rubella, mumps and varicella among school children in Madrid].
    Gil Miguel A; Astasio Arbiza P; Ortega Molina P; Domínguez Rojas V; González López A
    An Esp Pediatr; 1999 May; 50(5):459-62. PubMed ID: 10394183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early disappearance of maternal anti-measles, mumps, rubella, and varicella antibodies in Indian infants.
    Malshe N; Palkar S; Kulkarni R; Lalwani S; Mishra AC; Arankalle V
    Vaccine; 2019 Mar; 37(11):1443-1448. PubMed ID: 30765170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody persistence for 3 years following two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children.
    Knuf M; Zepp F; Helm K; Maurer H; Prieler A; Kieninger-Baum D; Douha M; Willems P
    Eur J Pediatr; 2012 Mar; 171(3):463-70. PubMed ID: 21935584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Prevalence of maternal measles, rubella, mumps and varicella antibodies in the first six months of life].
    Devecioğlu E; Gökçay G; Boran P; Eren T; Yılmaz G; Badur S
    Mikrobiyol Bul; 2018 Jul; 52(3):324-327. PubMed ID: 30156519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years.
    Vesikari T; Baer M; Willems P
    Pediatr Infect Dis J; 2007 Feb; 26(2):153-8. PubMed ID: 17259879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Marin M; Broder KR; Temte JL; Snider DE; Seward JF;
    MMWR Recomm Rep; 2010 May; 59(RR-3):1-12. PubMed ID: 20448530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The immunogenicity and safety of a tetravalent measles-mumps-rubella-varicella vaccine when co-administered with conjugated meningococcal C vaccine to healthy children: A phase IIIb, randomized, multi-center study in Italy.
    Durando P; Esposito S; Bona G; Cuccia M; Desole MG; Ferrera G; Gabutti G; Pellegrino A; Salvini F; Henry O; Povey M; Marchetti F
    Vaccine; 2016 Aug; 34(36):4278-84. PubMed ID: 27423382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reactogenicity and immunogenicity of a live attenuated tetravalent measles-mumps-rubella-varicella (MMRV) vaccine.
    Nolan T; McIntyre P; Roberton D; Descamps D
    Vaccine; 2002 Dec; 21(3-4):281-9. PubMed ID: 12450703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination measles, mumps, rubella and varicella vaccine.
    Arbeter AM; Baker L; Starr SE; Levine BL; Books E; Plotkin SA
    Pediatrics; 1986 Oct; 78(4 Pt 2):742-7. PubMed ID: 3763291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The combination measles, mumps, rubella and varicella vaccine in healthy children.
    Arbeter AM; Baker L; Starr SE; Plotkin SA
    Dev Biol Stand; 1986; 65():89-93. PubMed ID: 3030864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: a study of manufacturing consistency and persistence of antibody.
    Lieberman JM; Williams WR; Miller JM; Black S; Shinefield H; Henderson F; Marchant CD; Werzberger A; Halperin S; Hartzel J; Klopfer S; Schödel F; Kuter BJ;
    Pediatr Infect Dis J; 2006 Jul; 25(7):615-22. PubMed ID: 16804432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity and reactogenicity of tetravalent vaccine for measles, mumps, rubella and varicella (MMRV) in healthy children: a meta-analysis of randomized controlled trials.
    Leung JH; Hirai HW; Tsoi KK
    Expert Rev Vaccines; 2015; 14(8):1149-57. PubMed ID: 26081133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Second dose of measles-mumps-rubella-varicella vaccine (MMRV) and the risk of febrile convulsions.
    Schäfer W; Reinders T; Schink T
    Vaccine; 2022 Mar; 40(14):2168-2172. PubMed ID: 35232594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and safety of early vaccination with two doses of a combined measles-mumps-rubella-varicella vaccine in healthy Indian children from 9 months of age: a phase III, randomised, non-inferiority trial.
    Lalwani S; Chatterjee S; Balasubramanian S; Bavdekar A; Mehta S; Datta S; Povey M; Henry O
    BMJ Open; 2015 Sep; 5(9):e007202. PubMed ID: 26362659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children.
    Shinefield H; Black S; Digilio L; Reisinger K; Blatter M; Gress JO; Brown ML; Eves KA; Klopfer SO; Schödel F; Kuter BJ
    Pediatr Infect Dis J; 2005 Aug; 24(8):665-9. PubMed ID: 16094217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the measles, mumps and rubella immunisation programme in Spain by using a sero-epidemiological survey.
    Amela C; Pachón I; de Ory F
    Eur J Epidemiol; 2003; 18(1):71-9. PubMed ID: 12705626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Performance Characteristics of a Multiplex Flow Immunoassay for Detection of IgG-Class Antibodies to Measles, Mumps, Rubella, and Varicella-Zoster Viruses in Presumptively Immune Health Care Workers.
    Theel ES; Sorenson M; Rahman C; Granger D; Vaughn A; Breeher L
    J Clin Microbiol; 2020 Mar; 58(4):. PubMed ID: 32024728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ten-year follow-up on efficacy, immunogenicity and safety of two doses of a combined measles-mumps-rubella-varicella vaccine or one dose of monovalent varicella vaccine: Results from five East European countries.
    Prymula R; Povey M; Brzostek J; Cabrnochova H; Chlibek R; Czajka H; Leviniene G; Man S; Neamtu M; Pazdiora P; Plesca D; Ruzkova R; Stefkovicova M; Usonis V; Verdanova D; Wysocki J; Casabona G; Habib MA
    Vaccine; 2021 May; 39(19):2643-2651. PubMed ID: 33858718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunity of nursing students to measles, mumps, rubella, and varicella in Yozgat, Turkey.
    Kader Ç; Erbay A; Akça NK; Polat MF; Polat S
    Am J Infect Control; 2016 Jan; 44(1):e5-7. PubMed ID: 26442461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.